55
Paediatric Psychopharmacology. Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK).

Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Paediatric Psychopharmacology.

Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK).

Page 2: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Childhood pharmacokinetics

• Children have greater hepatic capacity • More glomerular filtration • Less fatty tissue • Less ability to store drugs in their fat • Due to quick elimination, half lives are shorter. • Stimulants, antipsychotics and tricyclic drugs

eliminated more rapidly.

Page 3: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Principles of prescribing

• Target symptoms, not diagnoses. • ‘off- label’ use, or unlicensed medications are

often necessary in paediatric practice. • Begin with less, go slow and be prepared to end

with more. • Multiple medications are often required in the

severely ill. • Allow time for an adequate time of treatment. • Where possible, change one drug at a time.

Page 4: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Autistic spectrum disorders. • Core deficits in 3 areas. • Language, social

interaction,behaviour (stereotypies, restricted, unusual patterns of interest)

• Comorbidity with mental retardation, ADHD, epilepsy, anxiety, OC features, mood disorders,self harm, irritability, aggression, sleep disurbances.

Page 5: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

ASD…

• Response to medications may be less robust,higher incidence of adverse effects.

• Conservative dosing and titration of doses. • Key studies: research units on pediatric

psychopharmacology autism network- Risperidone trials

• Research units on pediatric psychopharmacology Autism network – Methylphenidate Trial.

Page 6: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Adhd symptoms in ASD • As per RUPP Autism

Network, and Santosh et al: positive benefits of methylphenidate.

• Variable responses in children with ASD and adhd symptoms.

• Either marked improvement with few side effect or poor response with problematic side effects.

• Limited efficacy in this group

Page 7: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

ASD with adhd symptoms

• Low doses ie 0.125mg/kg, with small increments. • Stop immediately if behaviour deteriorates, or

unacceptable side effects. • Small open label trials show Atomoxetine may be

useful, RCTs awaited. • May be more effective in milder ASD symptoms. • Some evidence for risperidone, clonidine. • None for anticonvulsants, SSRI, benzodiazepines.

Page 8: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Irritability in ASD ( aggression, tantrums, self injurious behaviour)

• Duration of treatment is around 6-12 months • FDA approved are risperidone and Aripiprazole. • Recent meta-analysis of short term aripiprazole

and children 6-17 years , found a significant reduction in irritability with a moderate effect size.

• Cochrane review say it is useful in managing irritability, hyperactivity and stereotypies and children with ASD, but has side effects of weight gain, sedation, sialorrhoea and EPS.

Page 9: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Irritability in ASD ( aggression, tantrums, self injurious behaviour)

• Recommended dose is 5-15mg. • Effectiveness of olanzapine and Ziprasidone

not tested in powered RCTs. • Some data shows combination of risperidone

and topiramate is better than risperidone alone.

• Mood stabilizers not as effective as SGAs for irritability in ASD.

Page 10: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Restricted repetitive behaviours and interests domain.

• Important treatment target to improve overall outcomes in ASD.

• Behavioural therapies are first line. • Severe behaviours, impacting education,

social performance, risk to others and self harm should be treated.

• SSRI’s studied are fluoxetine, sertraline, fluvoxamine, citalopram and escitalopram.

Page 11: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

RRBI’s

• Inconsistent benefits from SSRI’s. • Side effects of increased activation and

agitation. • Start with 2.5mg fluoxetine, with mean dose

being 10mg. • Clomipramine has modest effectiveness. • Others: Risperidone, anticonvulsants, and

neuropeptide Oxytocin.

Page 12: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Social and communication impairment

• No drug shown to improve core social and communication impairment.

• Risperidone has a secondary effect through improvement in irritability.

• Most promising: glutamatergic drugs and oxytocin

Page 13: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Sleep disturbance in ASD • Melatonin effective, as per

17 studies. • Doses range from 1-10mg. • Well tolerated • Risperidone may benefit in

those with extreme irritability.

• If child is anxious/depressed, antidepressants.

• If due to hyperarousal,then clonidine or clonazepam.

Page 14: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Pathologic aggression in ASD

• It may be severe, destructive,chronic and unresponsive to psychosocial interventions.

• Need to understand what drives the aggression. • As per Barzman and Findling, medications to be

used only if • Current treatments not helping • Underlying conditions adequately treated • All behavioural and psychological methods not

helping to ensure safety.

Page 15: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Pathologic aggression in ASD. • Most common

comorbidity is bipolar disorder, psychosis, and LD.

• No data for children less than 5 years of age.

• Most evidence for risperidone in aggression.

• Fewer data for olanzapine, quitepine, aripiprazole, and clozapine.

Page 16: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Pathologic aggression in ASD. • Recent systematic review

highlights importance of safety monitoring.

• SGAs cause weight gain, metabolic and hormonal imbalance.

• Weight gain worse in children than adults.

• Moodstabilizers lithium and sodium valproate effective in aggression.

Page 17: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Psychosis in Children & Adolescents.

• Onset of schizophrenia is rare prior to 13 years of age, it increases in adolescence .

• 3 major RCTs with FGAs. • High rates of EPS, treatment emergent dyskinesias, and

sedation. • Should be avoided in children. • Many RCTs for SGAs in EOSS. • Olanzapine, risperidone , aripiprazole effective in

psychosis treatment. • Some evidence for quetiapine, but some safety

concerns for Ziprasidone.

Page 18: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Psychosis…

• This population more prone to neutropenia and seizures from clozapine, than adults.

• NICE recommends oral antipsychotics, family interventions and individual CBT.

Page 19: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Drug treatment of psychosis.

First choice Allow patient to choose from

Aripirazole (to 10mg)

Olanzapine (to 10mg)

Risperidone (to 3mg)

Second choice Switch to alternative from list above

Third choice Clozapine

Page 20: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Anxiety disorders in children and adolescents.

• Fear and worry are common and normal in children.

• But Anxiety disorders begin in childhood. • Most common with overall prevalence 8%-

30%. • Exclude other diagnoses.

Page 21: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Anxiety disorders • SSRIs treatment of choice

in moderate to severe anxiety

• Several RCTs have shown benefit in GAD,social phobia,seraration anxiety disorder,selective mutism.

• Consider trial of stopping meds after 1 year of no symptoms.

Page 22: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Anxiety disorders • Venlafaxine tested in 2 RCTs

with RR of response of 1.46 over placebo.

• Can be considered 2nd line, when SSRIs ineffective.

• Open label studies suggest buspirone and mirtazepine may be useful, though efficacy not known.

• Benzodiazepines may potentiate initial SSRIs, but not advisable.

Page 23: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Anxiety disorders

• AACAP, NICE and Maudsley guidelines recommend psychotherapy in mild anxiety disorders.

• Multimodal treatment of psycho-education, exposure based CBT and only if no/partial response, to add medications.

• Always start at low doses and titrate at regular intervals, monitoring for side effects.

• For preschoolers, no RCTs done, but case reports suggest benefit with fluoxetine and buspirone.

Page 24: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Obsessive compulsive disorders in Children

Moderate or severe

impairment

Offer CBT(+ERP)involve

family Consider SSRI

SSRI + CBT Different SSRI, clomipramine

Page 25: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

OCD in children

• POTS ( pediatric OCD treatment study) • FDA approved fluvoxamine, fluoxetine,sertraline ,

Clomipramine. • Begin with CBT, later combine with an SSRI. • Refractory OCD in children: 1/4th don’t respond • risperidone,( off label) augmentation. • Ketamine and riluzole are not effective in

children.

Page 26: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Posttraumatic stress disorder. • Trauma focussed CBT • EMDR ( eye movement

desensitization and reprocessing.

• CBITS ( cognitive behavioural for trauma in schools)

• SPARCS ( structured psychotherapy for Adolescents responding to chronic stress)

Page 27: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

PTSD…..

• TARGET ( Trauma affect regulation: guide for education and therapy.)

• Crisis Intervention /Psychological Debriefing

Page 28: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

PTSD….

• Alpha-2 agonists ie clonidine for dysregulation of the noradrenergic system

• Beta- antagonists propranolol, improves hyperarousal and intrusive thoughts

• Clonidine may reduce reenactment symptoms in children

• In young children withhyperarousal, impulsivity and agitation show improvement with clonidine 0.05-0.1 mg.

Page 29: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

PTSD…

• Due to comorbidity with depressive disorders, anxiety disorders,behavioural problems, multitude of medications used to ameliorate symptoms of PTSD.

• FDA approved is Sertraline and Paroxetine in adults, scant evidence for its use in the youth.

• No superiority of sertraline and citalopram over placebo, in several trials.

• In PTSD with burns, SSRIs found effective.

Page 30: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

PTSD….

• SGAs like risperidone, olazapine, quetiapine, ziprasidone,and aripiprazole studied with mixed results in adults.

• Risperidone and aripiprazole tried in children • Carbamazepine and valproex have been used in

some trials, with some improvement with higher doses.

• Benzodiazepines given, but no controlled trials. • For comorbid depression, anxiety, SSRIs

recommended.

Page 31: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Use of melatonin in Insomnia in children

Page 32: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Melatonin.

Page 33: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Conduct Disorder

• Many diagnoses complicated by aggressive and oppositional tendencies.

• Comorbid disorders should be the primary target of pharmacotherapy.

Page 34: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Conduct disorder..

• Moodstabilizers ie divalproex sodium, lithium.

• Antipsychotics esp. atypical antipsychotics.

• Stimulants. • Dysphoric aggression

more responsive than predatory aggression, to medications.

Page 35: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Oopositional Defiant disorder. • Mostly comorbid with

ADHD, substance use, delinquency.

• Recent trial showed use of extended release methylphenidate in ODD comorbid with ADHD and with no ADHD.

• 1 study showed benefit of atomoxetine in ODD , but not replicated in a different study.

Page 36: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Oppositional defiant disorder… • Several studies of typical

and atypical antipsychotics used as adjuncts for treatment of aggression in mental retardation and pervasive developmental disorders.

• AACAP recommends multimodal approach of individual and family psychosocial interventions, parent training interventions.

Page 37: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Oppositional defiant disorder

• Pharmacotherapy used to treat specific ODD

symptoms or comorbid conditions ie mood disorder or ADHD, which may improve ODD symtoms.

Page 38: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Tics and Tourette’s syndrome. • Tics occur in 5-20% of children. • Tourette’s syndrome (

persistent motor and vocal tics) occurs in 1% of children.

• Most tic disorders are transient, abate with age and don’t adversely affect functioning.

• Tics also wax and wane , increase in stress, inactivity and fatigue.

• Tics are 2-3 times more common in boys, than girls.

Page 39: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Tics and Tourettes’s Syndrome… • Mostly, OCD, ADHD, depression, anxiety and

behavioural problems are more prevalent. • Need to treat comorbid disorders, before assessing

level of disability caused by tics. • Most tics do not require pharmacological treatments. • Education for the child, family and schools are

important. • RCT of Behavioural interventions showed effect size of

0.68, similar to medications for tics. • Habit reversal and exposure and response prevention

are treatments of choice.

Page 40: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Tics and Tourette’s disorder. • FDA approved is Pimozide for managing tics. • Controlled clinical trials approve of : • Clonidine 3-5 mg/kg. • Haloperidol • Risperidone • Recent studies show Aripiprazole • Small and open studies suggest Olanzapine, quitepine. • Also Sulpiride and Ziprasidone • No effect for clozapine. • Most authors recommend second generation APDS.

Page 41: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Tics and Tourette’s disorder.

• Botulinum toxin used to treat painful focal motor tics, est affecting neck muscles.

• In subgroup of children with tics/and or OCD with streptococcal infection ie PANDAS, immunomodulatory therapy needed.

• Consensus that tics/OCD treated in usual way. • A short course of antibiotics for any child

presenting with acute onset tics and /or OCD.

Page 42: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Disruptive mood dysregulation disorder

• Symptomatic intervention • Etiology not well understood • If similar to bipolar disorder, treat with SGAs and

Mood Stabilizers. • If similar to depression, and anxiety, treat with

SSRIs. • If comorbid with ADHD, to give stimulants. • Scant studies so far. • Psychosocial interventions and CBT.

Page 43: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Early onset Bipolar Disorder

• Most well studied are atypicals and mood stabilizers.

• 8 RCTs shown efficacy of atypicals for ages 10-17 years, in both mixed states and bipolar disorder. ie. Olanzapine, quetiapine, risperidone,aripiprazole, ziprasidone.

• In comparative studies, quetiapine and risperidone found more efficacious than valproate, in reducing manic symptoms.

Page 44: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Early onset Bipolar Disorder.

• Lithium efficacious in aggressive mania in adolescents.

• Open trial of Lamotrigine in bipolar depression, supports its use in youth.

• Mood stabilizers overall less effective in BPD in children and adolescents.

• Current evidence suggests faster and more robust response with atypicals, though addition of another drug required when there is partial recovery.

Page 45: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Depressive disorders. • Fluoxetine and escitalopram

have FDA approval in adolescents.

• Sertraline 50- 200mg has been shown to provide efficacy in 2 big trials

• Starting doses of SSRIs lower in children as compared to adolescents.

• Venlafaxine effective in TORDIA study, but 2nd line treatment

• TCAs not recommended • Overall S/E of behavioural

activation with SSRIs.

• In 2004, FDA issued ‘blackbox’ warning with SSRIs.

• Several reviews since, concluded that there is no increased risk for suicide or serious suicide attempts after starting SSRIs.

Page 46: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Enuresis • Toilet training review. • Record keeping, star chart. • Restricting fluids at night. • alarm therapy triggered by

wet underwear. • TCAs • Desmopressin nasal spray.

(effect of 10- 90%) • Antidiuretic, reducing urine at

night. • a/e headache, nasal

congestion,epistaxis, stomachache.

• Reboxetine 4-8 mg.

Page 47: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Preschoolers.

• Preschool psychopharmacology working group released recommendations recently.

• Limited evidence base • Psychosocial

interventions always precede pharmacological management.

Page 48: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Preschoolers ADHD

• As per PATS, several small trials, methylphenidate is recommended as first-line treatment in ADHD in preschoolers.

Page 49: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Preschoolers disruptive behavioural disorders

• Risperidone as first line in disruptive behaviours and severe aggression, without ADHD.

Page 50: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Preschoolers major depressive disorder

• 1st line treatment is Fluoxetine

Page 51: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Preschoolers Bipolar disorder

• Most data on risperidone.

• Good efficacy and tolerability.

Page 52: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Preschoolers anxiety disorders

• Fluoxetine first choice for anxiety disorders.

• For OCD, fluoxetine , fluvoxamine and sertraline equally effective.

• For PTSD ,medications not recommended by the working group.

Page 53: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Preschoolers PDD.

• Risperidone approve by FDA for children as young as 5 yrs with aggression and irritability

Page 54: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Preschoolers primary sleep disorders.

• Only if sleep disturbance sufficiently compromises wellbeing and daytime functioning of the child, melatonin 1-3mg considered.

Page 55: Paediatric Psychopharmacology. · 2018. 12. 1. · • Key studies: research units on pediatric psychopharmacology autism network- Risperidone trials • Research units on pediatric

Thank you!